Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MK-1942 with Donepezil in Alzheimer's Disease
NCT04308304Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing MK-1942 + Donepezil with Placebo + Donepezil (2 arms). Primary endpoints: Number of Participants With ≥1 Adverse Event, Number of Participants Discontinuing From Study Therapy Due to an Adverse Event and 9 more. Started Feb 2021; status: completed.
02
Drugs
MK-1942
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04308304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04308304.